ArticleJournal of biomedical science2016
Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice.
Article in Journal of biomedical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 114 citations in OpenAlex.
- Trial
- Review
- Natural Molecules for Brain Health and Resilience.International journal of molecular sciences · 2026Review
- Nrf2-Activating Natural Compounds in Neurodegenerative Diseases: Targeting Oxidative Stress and Protein Aggregation.International journal of molecular sciences · 2026Review
- Beyond Neurotrophins: A Proposed Neurotrophic-Epigenetic Axis Mediated by Non-Coding RNA Networks forInternational journal of molecular sciences · 2026Review
- Recent Advances in Erinacine A: Preparation, Biological Activities, and Biosynthetic Pathway.Molecules (Basel, Switzerland) · 2026Review
- Yamabushitake Mushroom (International journal of molecular sciences · 2025Article
- Fungal Bioactive Compounds as Emerging Therapeutic Options for Age-Related Neurodegenerative Disorders.International journal of molecular sciences · 2025Review
- Olive mill solid waste induces beneficial mushroom-specialized metabolite diversity revealed by computational metabolomics strategies.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Two-Dimensional Chromatographic Isolation of High Purity Erinacine A fromJournal of fungi (Basel, Switzerland) · 2025Article
- Meroterpenoids from Terrestrial and Marine Fungi: Promising Agents for Neurodegenerative Disorders-An Updated Review.Current issues in molecular biology · 2025Review
- Theoretical Potential of Hericium Erinaceus Supplementation as an Add-On to Antipsychotics in Chronic and Treatment-Resistant Schizophrenia.Psychopharmacology bulletin · 2025Review
- Acute effects of a standardised extract ofFrontiers in nutrition · 2025Article
- Unveiling the role of erinacines in the neuroprotective effects ofFrontiers in pharmacology · 2025Review
- Exploring the Synergistic Effects of Erinacines on Microglial Regulation and Alzheimer's Pathology Under Metabolic Stress.CNS neuroscience & therapeutics · 2024Article
- Erinacenones A-L: Twelve New Isoindolinone Alkaloids from the Edible and Medicinal MushroomMolecules (Basel, Switzerland) · 2024Article
- A pilot pharmacokinetic and Metabolite identification study of Erinacine A in a Single landrace pig model.Heliyon · 2024Article
- Unveiling the Chemical Composition and Biofunctionality ofInternational journal of molecular sciences · 2024Review
- Antioxidants, Hormetic Nutrition, and Autism.Current neuropharmacology · 2024Review
- Navigating neurological disorders: harnessing the power of natural compounds for innovative therapeutic breakthroughs.EXCLI journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe fruiting body of Hericium erinaceus has been demonstrated to possess anti-dementia activity in mouse model of Alzheimer's disease and people with mild cognitive impairment. However, the therapeutic potential of Hericium erinaceus mycelia on Alzheimer's disease remains unclear. In this study, the effects of erinacine A-enriched Hericium erinaceus mycelia (HE-My) on the pathological changes in APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease are studied.
resultsAfter a 30 day oral administration to 5 month-old female APPswe/PS1dE9 transgenic mice, we found that HE-My and its ethanol extracts (HE-Et) attenuated cerebral Aβ plaque burden. It's worth noting that the attenuated portion of a plaque is the non-compact structure. The level of insulin-degrading enzyme was elevated by both HE-My and HE-Et in cerebral cortex. On the other hand, the number of plaque-activated microglia and astrocytes in cerebral cortex and hippocampus were diminished, the ratio of nerve growth factor (NGF) to NGF precursor (proNGF) was increased and hippocampal neurogenesis was promoted after these administrations. All the mentioned benefits of these administrations may therefore improve the declined activity of daily living skill in APPswe/PS1dE9 transgenic mice.
conclusionsThese results highlight the therapeutic potential of HE-My and HE-Et on Alzheimer's disease. Therefore, the effective components of HE-My and HE-Et are worth to be developed to become a therapeutic drug for Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.